PubMed Health⌕ Search

Biomedical subjects

Isaac Julius Asiedu-Gyekye

Publications and source records attributed to Isaac Julius Asiedu-Gyekye.

2 recordsLinked to original sources

Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model.

BACKGROUND: The purpose of this study was to ascertain the effect of Losartan, a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension, on the movement of proteins and fluids across the vascular compartment in ischemic cat brains. MATERIAL/METHODS: The experiments were carried out on anesthetized cats under artificial ventilation and autohemoperfusion of the brain with a stable volume of blood with the help of a resistograph. Cerebral ischemia was induced by a 15-minute arrest of the autohemoperfusion pump, tying various anastomoses in the neck region, and reducing arterial pressure to 40-30 mm Hg by hemorrhage with subsequent reinfusion of the lost blood. RESULTS: In the postischemic period in the cat brain, control experiments showed the onset of metabolic acidosis and an increase in permeability of the brain capillaries to fluids and protein molecules. Intravenous introduction of losartan, an angiotensin II receptor antagonist, at a dose of 3 mg x kg(-1) 10 minutes into the postischaemic period, enhanced the normalization of metabolic and transcapillary exchange. Thus vector permeability was reversed from blood-to-tissue in the control situation (without losartan) to tissue-to-blood during losartan administration. CONCLUSIONS: The results provide strong evidence that losartan may play a role in preventing cerebral edema, and that the renin-angiotensin system plays an important role in postischemic cerebrovascular events.

Angiotensin Receptor Antagonists↗

The "no-reflow" phenomenon in cerebral circulation.

BACKGROUND: The purpose of our research was to study the pattern of post-ischemic cerebral hemodynamic changes and observe the impact of enalapril on the course of these changes in cats. MATERIAL/METHODS: The experiments were carried out on anesthetized cats using the autohemoperfusion method in cerebral and peripheral vessels with a stable volume of blood. Transitional peripheral (lower limb) and brain ischemia was simulated by stopping the autohemoperfusion pump for 15 minutes, tying various anastomoses in the neck region, and reducing arterial blood pressure (ABP) to 40-30 mm Hg, followed by reinfusion of the shed blood. RESULTS: Intravenous administration of enalapril solution in a dosage of 0.25 mg kg-1 in the early phase of reperfusion (10 minutes into the postischaemic period) prevented the development of long-term "no-reflow"of cerebral blood flow, as observed in the controls. There was a 40.8+/-3.2% reduction of cerebrovascular tone, 39.3+/-3.1% in peripheral vessels, and 44.7+/-1.5% lower arterial blood pressure at the end of 120 minutes. CONCLUSIONS: Enalapril caused a reduction of cerebrovascular tone, completely eliminating the "no-reflow" syndrome after brain ischemia and somewhat potentiated the hyperperfusion phase. At the same time, the drug did not aggravate the general hypotension observed after ischemia in the controls.

Animals↗